Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AUPH 
Aurinia Pharmaceuticals Inc (AUPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: AUPH (3-star) is a STRONG-BUY. BUY since 32 days. Simulated Profits (19.89%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.14% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.09B USD | Price to earnings Ratio 28.3 | 1Y Target Price 16.67 |
Price to earnings Ratio 28.3 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 6 | Beta 1.44 | 52 Weeks Range 6.55 - 16.48 | Updated Date 12/17/2025 |
52 Weeks Range 6.55 - 16.48 | Updated Date 12/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 29.28% | Operating Margin (TTM) 40.49% |
Management Effectiveness
Return on Assets (TTM) 9.41% | Return on Equity (TTM) 20.65% |
Valuation
Trailing PE 28.3 | Forward PE 20.2 | Enterprise Value 1794982370 | Price to Sales(TTM) 7.86 |
Enterprise Value 1794982370 | Price to Sales(TTM) 7.86 | ||
Enterprise Value to Revenue 6.75 | Enterprise Value to EBITDA 17.34 | Shares Outstanding 131840559 | Shares Floating 128247904 |
Shares Outstanding 131840559 | Shares Floating 128247904 | ||
Percent Insiders 7.14 | Percent Institutions 50.75 |
About Aurinia Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 1999-01-26 | President, CEO & Director Mr. Peter S. Greenleaf M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.auriniapharma.com |
Full time employees 130 | Website https://www.auriniapharma.com | ||
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.